Navigation Links
Early administration of antiretroviral therapy can improve survival
Date:4/9/2009

ministration of the treatment difficult. With new families of drugs available and new, less toxic combinations, it is now possible to consider instating treatment earlier without unduly affecting the patient's quality of life.

The study published in The Lancet, in the framework of the Antiretroviral Therapy Cohort Collaboration, includes information from 15 international cohorts. Data were obtained from 21,247 patients who were followed up during the period prior to instatement of combined antiretroviral therapy and 24,444 patients who were followed up from the beginning of treatment. Waiting to administer the combined therapy until CD4 levels had fallen to between 251 and 350 cells/L was associated with a 28% higher rate of development of AIDS and death than beginning treatment when levels were between 351 and 450 cells/L. The adverse effects of delaying therapy were directly linked to the drop in the CD4 count. Waiting to treat until the CD4 count was below these levels was also associated with a higher mortality rate (13%), though the effect on mortality was smaller than the combined effect on developing AIDS and death.

The conclusion of the study is that the lowest level for initiating antiretroviral therapy is 350 cells/L. This will soon be indicated in the clinical guides and in clinical practice. The Gesida/National AIDS Plan guides are already being drawn up and will include the recommendation to initiated treatment before the CD4 count falls below 350 cell/L. The new recommended figure will probably be between 350 and 500 cells/L. The international clinical guides (both European and American), which will not be updated for some months, and the SMART clinical trial also suspected that antiretroviral therapy should begin before the CD4 count falls to 350 cells/L. Furthermore, the journal New England Journal of Medicine (

Contact: lex Argem
aargemi@clini.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection
2. Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
3. Early family ties: No sponge in the human family tree
4. Two innovative University of Texas at Austin biologists become HHMI Early Career Scientists
5. Two Hutchinson Center researchers named HHMI Early Career Scientists
6. Peter Baumann named Howard Hughes Medical Institute Early Career Scientist
7. Whitehead member Peter Reddien named HHMI Early Career Scientist
8. Deep-sea rocks point to early oxygen on Earth
9. No consistent advantage for planting soybean early
10. Study to evaluate success of parental involvement in early childhood education
11. International study identifies gene variants associated with early heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... species of fish, according to a new study ... tested fish anti-predator behaviour. , Three-spined sticklebacks ... when exposed to additional noise, whereas no effects ... author Dr Irene Voellmy of Bristol,s School of ... environments have increased substantially during the last few ...
(Date:7/24/2014)... A sake brewery has its own microbial terroir, meaning ... resemble those found in the product, creating the final ... the journal Applied and Environmental Microbiology . This ... census of a sake brewery. , Many sake ... author David A. Mills of the University of California, ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... diabetes places a huge burden on its victims and poses ... attacks and stroke cases, but also many other deleterious conditions, ... In Germany alone, some seven million people currently suffer from ... to reach 370 million by the year 2030. Type 2 ...
... A discovery by Monash University scientists could see humble ... ,lab-on-chip, devices capable of detecting diseases such as kidney ... researchers have used ordinary cotton thread and sewing needles ... which is the size of a postage stamp. ...
... may look identicalnot to mention drabto the human eye. But ... are essentially colorblind. A new study published online on February ... reveals that the fish can easily tell one species from ... patterns on their faces. Although scientists have long known ...
Cached Biology News:The pig and its pancreas 2The pig and its pancreas 3How long is a piece of thread? Long enough to save a life 2Fish can recognize a face based on UV pattern alone 2
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Feb. 5 Amicus Therapeutics (Nasdaq: FOLD ) announced ... Crowley as Chairman of the Board in addition to his ... will succeed Donald J. Hayden, Jr. , who will become ... to elect Mr. Crowley as Chairman of the Board reflects our ...
... Science , by researchers at Rothamsted Research (an institute ... Institute, and the Universities of Exeter, Greenwich and York, ... insects to undertake long-distance migrations, and highlights the remarkable ... cold British winters by migrating south in autumn to ...
... 4, 2010 -- Four Oak Ridge National Laboratory researchers ... research grants as part of the Department of Energy,s ... program, funded under the American Recovery and Reinvestment Act ... support exceptional researchers during the crucial early career years, ...
Cached Biology Technology:Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2Migrating insects fly in the fast lane 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3
... Kits without ammonium sulfate are compatible with ... as Taq and AmpliThem™™ DNA polymerases. You ... systems in one experiment by adding your ... the PreMixes supplied with the kit. This ...
... MasterAmp™ PCR Optimization Kits without ammonium sulfate ... in PCR, such as Taq and AmpliThem™™ ... performance of PCR systems in one experiment ... PCR primers into the PreMixes supplied with ...
... Optimization Kits with ammonium sulfate are compatible ... such as Tfl, Tth, and Pfu DNA ... of PCR systems in one experiment by ... primers into the PreMixes supplied with the ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
Biology Products: